Savara announces $75M royalty funding agreement

Savara (SVRA) announced a $75M royalty funding agreement with funds managed by RTW Investments, LP, subject to FDA approval of MOLBREEVI. The royalty financing will become available upon FDA’s approval of MOLBREEVI, and satisfaction of certain customary conditions. Under the terms of the agreement, RTW will receive a tiered single digit percentage of annual net sales of MOLBREEVI in the U.S. for the treatment of autoimmune PAP, subject to a cap.